|
시장보고서
상품코드
2084680
원추-간상세포 이영양증 시장 : 질환 종류별, 진단법별, 치료법별, 최종사용자별, 지역별Cone Rod Dystrophy Market, By Disease Type, By Diagnosis, By Treatment, By End User, By Geography |
||||||
원추-간상세포 이영양증 시장은 2026년에 1억 4,860만 달러 규모가 될 것으로 추정되며, 2033년까지 2억 3,780만 달러에 달할 것으로 예상됩니다. 2026년부터 2033년까지 CAGR 7%로 성장할 것으로 전망됩니다.
| 분석 범위 | 분석 상세 | ||
|---|---|---|---|
| 기준 연도 | 2025년 | 시장 규모(2026년) | 1억 4,860만 달러 |
| 실적 데이터 | 2020-2024년 | 예측 기간 | 2026-2033년 |
| 예측 기간 CAGR(2026-2033년) | 7.00% | 예측 금액(2033년) | 2억 3,780만 달러 |
원추-간상세포 이영양증(CRD)은 망막의 원추체 광수용세포가 먼저 변성되고, 이어서 봉체 광수용세포가 변성되는 일련의 희귀 유전성 질환으로, 이로 인해 중심 시력과 색각, 시력이 서서히 상실되며, 결국에는 주변 시야도 상실하게 됩니다. 원추체·봉체 근이영양증은 ABCA4, RPGR, CRX 유전자 등 30개 이상의 유전자에 영향을 미치는 광범위한 돌연변이에 의해 유발될 가능성이 있으며, 상염색체 우성, 열성 또는 X-연관 유전 양식으로 유전됩니다. 전 세계 유병률은 3만 명당 1명에서 4만 명당 1명으로 추정되며, CRD는 미충족 의료 수요가 매우 높은 분야입니다.
원추-간상세포 이영양증 시장은 진단, 지지요법, 저시력 재활 기술과 같은 여러 부문 외에도, 새롭고 선진적인 치료 옵션이 될 수 있는, 아직 발전 단계에 있지만 꾸준히 진전되고 있는 유전자 치료 및 세포 치료로 구성되어 있습니다. 시장 성장은 유전자 진단율의 상승, 유전성 망막 질환에 대한 임상시험의 확대, 다양한 희귀질환 치료제 이니셔티브를 통한 지원, 그리고 환자의 조기 진단 및 질병 진행 억제 요법의 가능성을 높이는 안과 유전자 치료의 혁신에 힘입어 촉진되고 있습니다.
시장 역학
세계 원추-간상세포 이영양증 시장은 유전자 치료 파이프라인의 확대, 질환 조기 진단을 위한 유전자 검사의 보급, 그리고 희귀 유전성 망막 질환 분야의 정밀 의학 분야에서 표적 치료법 및 혁신적인 접근법 개발을 위한 제약 기업의 연구개발 투자 증가에 힘입어 성장하고 있습니다. 차세대 염기서열 분석(NGS) 등의 신기술 보급, 일부 희귀질환 치료제(오르판 드럭)에 대한 인센티브 도입, 그리고 세포·유전자 치료에 대한 종합적인 포트폴리오의 지속적인 임상 개발은 원추-간상세포 이영양증의 조기 발견 및 치료 가능성을 높이고, 질병 수정 요법의 도입 가속화를 뒷받침하고 있습니다.
그러나 시장에는 환자 집단 내 근본적인 유전자 변이의 높은 이질성, 개발 및 치료 비용의 고비용, 임상시험에서 제한된 원추·봉상 근이영양증(CRD) 환자 집단으로부터 적절한 코호트 규모의 표본을 수집하는 데 따르는 복잡성 등 많은 제약이 존재합니다. 그럼에도 불구하고, CRISPR 기반 기술의 발전, 유효한 바이오마커를 규명하기 위한 연구 확대, 그리고 바이오의약품 기업과 공공 연구 기관 간의 전략적 제휴 확대는 원추-간상세포 이영양증 시장에 새로운 성장 기회를 가져다줄 것입니다.
본 보고서의 주요 특징
- 본 보고서는 각 부문의 잠재적 수익 기회를 밝히고, 이 시장의 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
- 또한, 시장의 촉진요인 및 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업들이 채택하는 경쟁 전략 등에 관한 중요한 인사이트도 제공하고 있습니다.
- 전 세계 원추-간상세포 이영양증 시장의 주요 기업 개요을 각종 지표(기업 개요, 제품 포트폴리오, 주요 동향, 재무 실적, 전략 등)를 바탕으로 수록하고 있습니다.
- 본 보고서의 인사이트를 바탕으로, 마케팅 담당자와 기업 경영진은 향후 제품 출시, 기술 업데이트, 시장 확대 및 마케팅 전략에 관해 충분한 정보를 바탕으로 의사결정을 내릴 수 있습니다.
- '세계 원추-간상세포 이영양증 시장' 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입 기업, 재무 분석가 등 이 업계의 다양한 이해관계자들을 대상으로 합니다.
- 이해관계자들은 전 세계 원추-간상세포 이영양증 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정을 보다 수월하게 할 수 있습니다.
목차
제1장 분석 목적과 가정
제2장 시장 전망
제3장 시장 역학·규제·동향 분석
제4장 세계의 원추-간상세포 이영양증 시장 : 질환 종류별(2021-2033년)
제5장 세계의 원추-간상세포 이영양증 시장 : 진단법별(2021-2033년)
제6장 세계의 원추-간상세포 이영양증 시장 : 치료법별(2021-2033년)
제7장 세계의 원추-간상세포 이영양증 시장 : 최종사용자별(2021-2033년)
제8장 세계의 원추-간상세포 이영양증 시장 : 지역별(2021-2033년)
제9장 경쟁 구도
제10장 애널리스트의 제안
제11장 참고문헌과 분석 방법
KSM 26.07.16Cone Rod Dystrophy Market is estimated to be valued at USD 148.6 Mn in 2026 and is expected to reach USD 237.8 Mn by 2033, growing at a compound annual growth rate (CAGR) of 7% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 148.6 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 7.00% | 2033 Value Projection: | USD 237.8 Mn |
Cone-rod dystrophy (CRD) is a group of rare inherited disorders in which the retina's cones photoreceptors deteriorate followed by rods, leading to the gradual loss of central and color vision and visual acuity, then loss of peripheral vision. Cone-rod dystrophy can result from a wide range of mutations affecting over 30 genes, such as the ABCA4, RPGR and CRX gene, and is inherited in autosomal dominant, recessive or X-linked patterns. With an estimated worldwide prevalence between 1 in 30,000 and 1 in 40,000 people, CRD represents an area of significant unmet need.
The cone rod dystrophy market comprises several segments including diagnostic, supportive care and low vision rehabilitation technologies, in addition to nascent but advancing gene and cell therapies that represent novel advanced treatment options. The market growth is stimulated by rising rates of genetic diagnosis, expanded inherited retinal disease clinical trials, support from various orphan drug initiatives and innovation in ocular gene therapies that enhance chances of prompt diagnosis and disease-modifying therapies for patients.
Market Dynamics
The global cone rod dystrophy market is driven by expanding gene therapies pipeline, growing adoption of genetic testing for early diagnosis of disease, and increasing R&D investment by the pharmaceutical companies in the development of targeted therapy and innovative approaches in the area of precision medicine in rare inherited retinal disorders. The rise in adoption of novel technologies like next-generation sequencing, the launch of several orphan drug incentives and ongoing clinical development of a comprehensive portfolio of cell and gene therapies have boosted the potential of early identification and treatment of cone rod dystrophy and supported the accelerated introduction of disease-modifying therapeutics.
However, a number of constraints are present in the market, such as high heterogeneity of the underlying genetic mutations in the disease population, high costs of development and treatment and the complexities involved in assembling appropriate cohort size samples from the limited CRD population in clinical trials. Nevertheless, developments such as CRISPR-based technology, broadening research in identifying effective biomarkers, along with expanding strategic alliances amongst biopharmaceutical firms and public research bodies will offer new opportunities for growth in cone rod dystrophy market.
Key Features of the Study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global cone rod dystrophy market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include SparingVision, Beacon Therapeutics, Nanoscope Therapeutics, JCyte, MeiraGTx, Spark Therapeutics, Ocugen, Inc., ProQR Therapeutics, Alkeus Pharmaceuticals, and BlueRock Therapeutics
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global cone rod dystrophy market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global cone rod dystrophy market
Market Segmentation
- Disease Type Insights (Revenue, USD Mn, 2021 - 2033)
- Cone-Rod Dystrophy
- Rod-Cone Dystrophy
- Diagnosis Insights (Revenue, USD Mn, 2021 - 2033)
- Genetic Testing
- Electroretinography (ERG)
- Optical Coherence Tomography (OCT)
- Fundus Autofluorescence (FAF)
- Others
- Treatment Insights (Revenue, USD Mn, 2021 - 2033)
- Supportive Care
- Pharmacological Therapy
- Gene Therapy
- Cell Therapy
- Retinal Prostheses and Visual Aids
- End User Insights (Revenue, USD Mn, 2021 - 2033)
- Hospitals
- Ophthalmology Clinics
- Specialty Eye Centers
- Research Institutes
- Others
- Regional Insights (Revenue, USD Mn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- SparingVision
- Beacon Therapeutics
- Nanoscope Therapeutics
- JCyte
- MeiraGTx
- Spark Therapeutics
- Ocugen, Inc.
- ProQR Therapeutics
- Alkeus Pharmaceuticals
- BlueRock Therapeutics
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Cone Rod Dystrophy Market, By Disease Type
- Global Cone Rod Dystrophy Market, By Diagnosis
- Global Cone Rod Dystrophy Market, By Treatment
- Global Cone Rod Dystrophy Market, By End User
- Global Cone Rod Dystrophy Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Disease Type Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Market Opportunities
- Regulatory Scenario
- Industry Trends
4. Global Cone Rod Dystrophy Market, By Disease Type, 2021-2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Cone-Rod Dystrophy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Rod-Cone Dystrophy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
5. Global Cone Rod Dystrophy Market, By Diagnosis, 2021-2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Genetic Testing
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Electroretinography (ERG)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Optical Coherence Tomography (OCT)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Fundus Autofluorescence (FAF)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
6. Global Cone Rod Dystrophy Market, By Treatment, 2021-2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Supportive Care
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Pharmacological Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Gene Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Cell Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Retinal Prostheses and Visual Aids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
7. Global Cone Rod Dystrophy Market, By End User, 2021-2033, (USD Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Ophthalmology Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Specialty Eye Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Research Institutes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Mn)
8. Global Cone Rod Dystrophy Market, By Region, 2021 - 2033, Value (USD Mn)
- Introduction
- Market Share (%) Analysis, 2026, 2029 & 2033, Value (USD Mn)
- Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Mn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Diagnosis, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Treatment, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Diagnosis, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Treatment, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Diagnosis, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Treatment, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Diagnosis, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Treatment, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Diagnosis, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Treatment, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Mn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Disease Type, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Diagnosis, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Treatment, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Mn)
- Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Mn)
- South Africa
- North Africa
- Central Africa
9. Competitive Landscape
- SparingVision
- Company Highlights
- Disease Type Portfolio
- Key Developments
- Financial Performance
- Strategies
- Beacon Therapeutics
- Company Highlights
- Disease Type Portfolio
- Key Developments
- Financial Performance
- Strategies
- Nanoscope Therapeutics
- Company Highlights
- Disease Type Portfolio
- Key Developments
- Financial Performance
- Strategies
- JCyte
- Company Highlights
- Disease Type Portfolio
- Key Developments
- Financial Performance
- Strategies
- MeiraGTx
- Company Highlights
- Disease Type Portfolio
- Key Developments
- Financial Performance
- Strategies
- Spark Therapeutics
- Company Highlights
- Disease Type Portfolio
- Key Developments
- Financial Performance
- Strategies
- Ocugen, Inc.
- Company Highlights
- Disease Type Portfolio
- Key Developments
- Financial Performance
- Strategies
- ProQR Therapeutics
- Company Highlights
- Disease Type Portfolio
- Key Developments
- Financial Performance
- Strategies
- Alkeus Pharmaceuticals
- Company Highlights
- Disease Type Portfolio
- Key Developments
- Financial Performance
- Strategies
- BlueRock Therapeutics
- Company Highlights
- Disease Type Portfolio
- Key Developments
- Financial Performance
- Strategies
10. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
11. References and Research Methodology
- References
- Research Methodology
- About us
